Falcon Point Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Falcon Point Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-287,809	Closed	-$4.13M	–	111
2016 Q2	$4.13M	Buy	287,809 +9,816	+4%	+$133K	0.71%	47
2016 Q1	$3.32M	Buy	277,993 +259,390	+1,394%	+$2.72M	0.57%	47
2015 Q4	$248K	Buy	18,603 +1,247	+7%	+$15.3K	0.05%	107
2015 Q3	$186K	Sell	17,356 -19,683	-53%	-$215K	0.07%	117
2015 Q2	$298K	Buy	+37,039	New	+$272K	0.1%	106

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Falcon Point Capital's LXRX Position: Q3 2016 in Review

Falcon Point Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2016, closing a stake of 287,809 shares — an estimated $4.13M sold.

Falcon Point Capital first reported a position in LXRX in Q2 2015 and held it in 5 quarters. The position peaked at $4.13M in Q2 2016. 144 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

Falcon Point Capital reported no remaining Lexicon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Falcon Point Capital sold 287,809 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $4.13M.
Falcon Point Capital first reported a position in Lexicon Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Falcon Point Capital's Lexicon Pharmaceuticals position peaked at $4.13M in Q2 2016.
144 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Falcon Point Capital's 13F filing for Q3 2016, filed 8 Nov 2016.